Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead
Compugen Ltd (CGEN) reported Q3 2026 revenue of $3.8M, doubling from the prior year. CEO Dr. Eran Ophir discussed milestones with AstraZeneca and Gilead, including potential payments and clinical trial updates. The company has $117.5M in cash and expects funding into 2029. Clinical trials for COM701 and GS-0321 are progressing, with data expected in 2027.
How this was made

The 30-second read
Why it matters
The disclosed cash position and pending milestone upside may prompt short‑term buying interest, but the small scale of revenue limits broader market impact.
Market read
Primary relevance to CGEN shareholders; limited spillover to biotech sector.
What to watch
Potential dilution from future financing rounds and execution risk of multiple Phase 3 trials could weigh on valuation.
Background
Compugen Ltd (NASDAQ: CGEN) held its Q3 2026 earnings call, providing updated financials and milestone payment details from its collaborations with Gilead and AstraZeneca.
Ticker impact
Q3 2026 earnings disclosed revenue of $3.8M, cash $117.5M, $90M received from Gilead and up to $758M in future milestones.
modest upside as investors price in cash runway and potential milestone payments
The company reported doubled revenue YoY and a strong cash position, but no guidance; market reaction likely limited to short‑term speculative interest.
Market effects
Highlights ongoing partnership activity between biotech firms and big pharma (Gilead, AstraZeneca) in immuno‑oncology.
Limited to US biotech micro‑cap segment; no broader market effect.
Minimal, confined to niche oncology pipeline investors.
Counterpoint
Despite cash runway, the lack of near‑term data readouts and modest revenue suggest the stock may remain stagnant or face downside pressure.
Key entities
- CompanyCompugen Ltd
Biotech company developing immuno‑oncology therapies.
- PartnerGilead Sciences
Pharma partner providing milestone payments to Compugen.
- PartnerAstraZeneca
Pharma partner with milestone agreements.



